Current status of biosimilars in the treatment of inflammatory bowel diseases - Wikidata - wikimedia - TriplyDB

Current status of biosimilars in the treatment of inflammatory bowel diseases

Current status of biosimilars in the treatment of inflammatory bowel diseases

http://www.wikidata.org/entity/Q26765350

about

Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model.Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.

P2860

Q38708927-C4E76EE3-98FE-47F2-9846-910EBCD04841 Q39016810-0EB06FF1-3588-4A02-9264-A7E44FC163FA Q40976054-D8FC7604-AB7B-4A50-9934-42B4B973F6DA Q42316823-06D5543A-2383-485A-890B-42B73481AD18 Q48502863-8D114F94-8839-4995-A18B-2A59E7ACA3A5 Q49596689-4098FCDF-B4A6-4678-B01B-B59D717D0F8D

P2860

Current status of biosimilars in the treatment of inflammatory bowel diseases

http://www.wikidata.org/entity/Q26765350

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Current status of biosimilars in the treatment of inflammatory bowel diseases

@ast

Current status of biosimilars in the treatment of inflammatory bowel diseases

@en

Current status of biosimilars in the treatment of inflammatory bowel diseases

@nl

type

label

Current status of biosimilars in the treatment of inflammatory bowel diseases

@ast

Current status of biosimilars in the treatment of inflammatory bowel diseases

@en

Current status of biosimilars in the treatment of inflammatory bowel diseases

@nl

prefLabel

Current status of biosimilars in the treatment of inflammatory bowel diseases

@ast

Current status of biosimilars in the treatment of inflammatory bowel diseases

@en

Current status of biosimilars in the treatment of inflammatory bowel diseases

@nl

P1433

Q26765350-EA98E849-3574-4039-BB7A-093CA5063398

P1476

Q26765350-DBD12211-A699-4535-9E61-36E14E75AD4A

P2093

Q26765350-EC3A0182-40B6-4161-AB38-CB3F0978FA96

P2860

Q26765350-0509D63D-7305-4339-B733-7990ADD4EC65

Q26765350-065398A5-6F0C-426C-912E-148CF25839C1

Q26765350-0D3DFBD1-81B8-4A33-8584-D5823B919DF0

Q26765350-20B30A30-77FD-41DA-A589-559DA55A1B2E

Q26765350-2793A6D3-E040-4512-B82B-57ED909B8DBB

Q26765350-30A8F715-2B38-406B-B188-6F09BD061177

Q26765350-36BE3C2F-70BA-443D-B2B2-5A683AE4AA94

Q26765350-560C753A-D9F7-45B8-BCBF-C7EF3512CF78

Q26765350-5EFDA53E-7E9D-4A26-81BA-91F7D879493B

Q26765350-5FA8AB64-F599-4E16-9AD9-F4801CC8EB0F

P304

Q26765350-4E48D4FC-C4B7-4673-A0DF-D807EE3EB423

P31

Q26765350-0EE3F031-2C69-4B16-8B8E-810744758DD3

P356

Q26765350-C9E69090-1EF2-4609-858A-9C667EFAAF7A

P407

Q26765350-9C8F4CED-53CC-4788-A1FF-0B4DED8FC1FC

P433

Q26765350-A78CACFE-DEFC-49A8-850D-1412906D58F3

P478

Q26765350-C9E2BB59-40F6-4E41-9D62-2E97A040A589

P577

Q26765350-A6B92B61-D012-4CDD-874E-61ABA0FA0E6D

P5875

Q26765350-183CC5DD-D4DA-41C4-99E2-4BFCAA825C98

P698

Q26765350-DA8857CF-B49F-44DC-A46A-B966C32336F9

P921

Q26765350-2F9DA830-2B00-4462-9A44-664AA0C8B967

P932

Q26765350-57D8CE74-F1C2-4E13-BCDF-246B23CA2D06

P356

IR.2016.14.1.15

P1433

Intestinal research

P1476

Current status of biosimilars in the treatment of inflammatory bowel diseases

@en

P2093

Dong Il Park

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary?

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.

Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.

Inflammatory Bowel Disease in Asia: The Challenges and Opportunities.

Immunologic mechanisms of EPO-associated pure red cell aplasia.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications.

P304

15-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5217/IR.2016.14.1.15

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294732136

http://www.w3.org/2001/XMLSchema#string

P698

26884730

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

4754516

http://www.w3.org/2001/XMLSchema#string